Equities

Adial Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ADIL:NAQ

Adial Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.47
  • Today's Change-0.06 / -2.37%
  • Shares traded51.14k
  • 1 Year change-87.41%
  • Beta1.3156
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.05m
  • Incorporated2017
  • Employees5.00
  • Location
    Adial Pharmaceuticals Inc1180 SEMINOLE TRAIL, SUITE 495CHARLOTTESVILLE 22901United StatesUSA
  • Phone+1 (434) 422-9800
  • Fax+1 (302) 655-5049
  • Websitehttps://www.adialpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
InMed Pharmaceuticals Inc4.51m-7.66m2.39m13.00--0.2398--0.5312-4.08-4.081.723.420.45773.0920.23---77.84-87.37-93.34-107.4929.73---170.07-356.165.30--0.00--7.50---6.34------
Enzolytics Inc0.00-119.19k2.42m2.00---------0.106-0.1060.00-1.040.00-------369.52-----------------4.30-----100.00---9.35------
Artelo Biosciences Inc0.00-12.88m2.42m7.00---------15.97-15.970.00-0.63010.00----0.00-343.49---1,530.48-------------44.72---------31.07------
Shuttle Pharmaceuticals Holdings Inc0.00-10.71m2.55m9.00--0.8419-----25.86-25.860.001.130.00----0.00-507.78---3,614.50--------------0.2305-------38.71------
Psyence Biomedical Ltd-100.00bn-100.00bn2.62m12.00--0.0103----------247.64----------------------------0.00------101.98------
ProtoKinetix, Inc.0.00-376.18k2.62m0.00--10.44-----0.001-0.0010.000.00060.00-------78.62-530.88-117.20-607.05------------0.00------12.34--18.34--
Azitra Inc0.00-11.12m2.66m12.00--0.4043-----5.49-5.490.000.40660.00----0.00-157.91---203.88--------------0.1197---98.91--29.05------
Adial Pharmaceuticals Inc0.00-8.05m2.74m5.00--0.5228-----23.22-23.220.004.720.00----0.00-130.16-205.76-155.01-274.10-----------27.380.00-------88.48------
Dermata Therapeutics Inc0.00-8.85m2.74m8.00--0.2452-----28.37-28.370.004.690.00----0.00-150.49-136.32-203.36-201.56------------0.00-------57.64------
Vaccinex Inc601.00k-18.63m2.76m23.00------4.59-9.91-9.910.2864-0.92950.193--0.668226,130.44-598.49-299.11---------3,100.50-3,700.14---149.88----5.442.827.98---22.36--
Propanc Biopharma Inc0.00-67.00m2.89m1.00--0.2345-----13.54-13.540.000.8510.00----0.00-869.88---1,782.95-------------74.430.0492-------2,826.43------
Enveric Biosciences Inc0.00-11.25m3.13m5.00--0.1421-----94.63-94.630.0015.830.00----0.00-212.68-146.94-262.78-198.90------------0.00------45.16------
Hcw Biologics Inc422.03k-22.21m3.17m36.00------7.50-13.96-13.960.2716-0.80380.0162--1.2411,723.06-46.35-53.89---66.1020.00---2,855.77-545.79---42.261.45---9.68---20.12---29.10--
Data as of Mar 02 2026. Currency figures normalised to Adial Pharmaceuticals Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.